Hemostatic properties and protein expression profile of therapeutic apheresis plasma treated with amotosalen and ultraviolet A for pathogen inactivation.
Fiche publication
Date publication
septembre 2016
Journal
Transfusion
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GACHET Christian
Tous les auteurs :
Ohlmann P, Hechler B, Chafey P, Ravanat C, Isola H, Wiesel ML, Cazenave JP, Gachet C
Lien Pubmed
Résumé
The INTERCEPT Blood System (IBS) using amotosalen-HCl and ultraviolet (UV)A inactivates a large spectrum of microbial pathogens and white blood cells in therapeutic plasma. Our aim was to evaluate to what extent IBS modifies the capacity of plasma to generate thrombin and induces qualitative or quantitative modifications of plasma proteins.
Référence
Transfusion. 2016 Sep;56(9):2239-47